In this nationwide, population-based cohort study of CVD risk in more than 30 000 men with type 2 diabetes with 11 years follow-up, men receiving GnRH agonists had an increased predicted 5-year CVD risk score. Here, GNRH1 is linked to type 2 diabetes mellitus.